Phase 2 N=44 Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Drug-Related Serious Adverse Events (SAEs) — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=178 A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
RSV Infection
Primary: Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load — 134.70; 113.51; 624.30; 80.61 hours*log10 copies/milliliter (mL) — p=< 0.001
Phase 2 N=30 Convalescent Plasma for Patients With COVID-19
Coronavirus Infection · Coronavirus · COVID
Primary: Change in Respiratory Disease Severity — 251; 276 ratio
Phase 2 N=66 Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Stasis Dermatitis
Primary: Percent Change From Baseline in Total Sign Score (TSS) at Week 6: In-person Assessment — -18.07; -32.44 Percent change — p=0.0299
Phase 2 N=77 Liposome Bupivacaine Interscalene Total Shoulder
Acute Pain
Primary: Total Opioid Use — 22.5; 30.0 mg (morphine equivalent)
Phase 2 N=50 Working Memory Training Combined With Transcranial Magnetic Stimulation in Smokers
Tobacco Use Disorder
Primary: Time to Lapse on a Smoking Lapse Analogue Task — 16.11; 38.0; 26.36; 15.25 minutes
Phase 2 N=437 A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Partial Epilepsy
Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — -24.0; -35.5; -55.0; -55.0 percent change — p=<0.001
Phase 2 N=14 Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Dyskinesia · Parkinson's Disease
Primary: Least Squares Mean Dyskinesia Severity Area Under the Curve (AUC) Score As Assessed By Modified Movement Disorder Society-Unified Dyskinesia Rating Scale (MDS-UDysRS)…
Phase 2 N=40 Calcium Chloride for Prevention of Uterine Atony During Cesarean
Uterine Atony · Uterine Atony With Hemorrhage · Cesarean Section Complications
Primary: Uterine Atony — 4; 10 Participants
Phase 2 N=32 Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Breast Cancer
Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants
Phase 2 N=19 Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage III Prostate Cancer
Primary: Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria — 5; 3 Participants — p=0.46
Phase 2 N=17 Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
B-cell Malignancies
Primary: Part 1 and Part 2: Number of Participants With Adverse Events — 3; 4; 5; 274 Participants
Phase 2 N=70 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Primary: Objective Response Rate (ORR)
Phase 2 N=123 Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24 — 93.1; 100.0; 90.3; 90.3 Percentage of participants
Phase 2 N=43 CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Bladder Cancer
Primary: Objective Response Rate (ORR) — 1; 2 Participants